Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Blood|January 6, 2018
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myelomaEnrico Caserta, Junie Chea, Megan Minnix, et al.
Blood|June 20, 2023
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockadeMatthew Mei, Lu Chen, James Godfrey, et al.
JCI Insight|October 9, 2019
MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophagesJihane Khalife, Jayeeta Ghose, Marianna Martella, et al.
Iscience|July 18, 2022
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variantsFlavia Chiuppesi, John A Zaia, Katelyn Faircloth, et al.
Regional Anesthesia and Pain Medicine|October 5, 2025
Spinal cord stimulation plus conventional medical management versus conventional medical management alone for severe, non-surgical, refractory back pain: a randomized clinical trial followed by crossoverJames North, Aaron Calodney, Drew Trainor, et al.
Blood|March 22, 2022
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEMatthew G Mei, Hun Ju Lee, Joycelynne M Palmer, et al.
Breast Cancer Research and Treatment|May 27, 2015
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)Virginia G Kaklamani, Jacqueline S Jeruss, Elisha Hughes, et al.
Neuromodulation : Journal of the International Neuromodulation Society|March 12, 2014
Use of a newly developed delivery device for percutaneous introduction of multiple lead configurations for spinal cord stimulationLouis J Raso, Timothy R Deer, Sandford M Schocket, et al.
The Journal of Clinical Investigation|April 8, 2025
Identification of CD84 as a potent survival factor in acute myeloid leukemiaYinghui Zhu, Mariam Murtadha, Miaomiao Liu, et al.
Pageof 5